SPYRE THERAPEUTICS INC.

NASDAQ: SYRE (Spyre Therapeutics, Inc.)

Kemas kini terakhir: 24 Nov, 11:46PM

26.97

2.71 (11.17%)

Penutupan Terdahulu 24.26
Buka 24.95
Jumlah Dagangan 912,989
Purata Dagangan (3B) 846,525
Modal Pasaran 2,092,659,584
Harga / Jualan (P/S) 650.22
Harga / Buku (P/B) 8.67
Julat 52 Minggu
10.91 (-59%) — 29.06 (7%)
Tarikh Pendapatan 4 Nov 2025
EPS Cair (TTM) -3.06
Jumlah Hutang/Ekuiti (D/E MRQ) 0.06%
Nisbah Semasa (MRQ) 8.06
Aliran Tunai Operasi (OCF TTM) -169.86 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -68.57 M
Pulangan Atas Aset (ROA TTM) -25.34%
Pulangan Atas Ekuiti (ROE TTM) -65.82%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Spyre Therapeutics, Inc. Menaik Menurun

AISkor Stockmoo

1.8
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 4.0
Purata 1.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SYRE 2 B - - 8.67
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
QURE 1 B - - 5.81
SANA 1 B - - 6.10
NKTR 1 B - - 13.66

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 8.71%
% Dimiliki oleh Institusi 106.07%
Julat 52 Minggu
10.91 (-59%) — 29.06 (7%)
Julat Harga Sasaran
43.00 (59%) — 70.00 (159%)
Tinggi 70.00 (BTIG, 159.55%) Beli
Median 64.00 (137.30%)
Rendah 43.00 (Deutsche Bank, 59.44%) Beli
Purata 59.00 (118.76%)
Jumlah 3 Beli
Harga Purata @ Panggilan 19.91
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Jones Trading 01 Dec 2025 64.00 (137.30%) Beli 28.66
Deutsche Bank 26 Sep 2025 43.00 (59.44%) Beli 16.24
BTIG 16 Sep 2025 70.00 (159.55%) Beli 14.82

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
05 Dec 2025 Pengumuman Spyre Therapeutics Announces Grants of Inducement Awards
07 Nov 2025 Pengumuman Spyre Therapeutics Announces Grants of Inducement Awards
04 Nov 2025 Pengumuman Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04 Nov 2025 Pengumuman Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
29 Oct 2025 Pengumuman Spyre Therapeutics to Participate in Upcoming November Investor Conferences
24 Oct 2025 Pengumuman Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
15 Oct 2025 Pengumuman Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
13 Oct 2025 Pengumuman Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
13 Oct 2025 Pengumuman Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
05 Oct 2025 Pengumuman Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
03 Oct 2025 Pengumuman Spyre Therapeutics Announces Grants of Inducement Awards
15 Sep 2025 Pengumuman Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda